Hereditary Angioedema Therapeutics Market Size & Growth Forecast 2027–2036, By Segments (Treatment, End-use, Route of Administration), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Hereditary Angioedema Therapeutics Market size was more than USD 4.1 billion in 2026 and is set to grow at a 9.88% CAGR between 2027 and 2036, attaining USD 10.52 billion by 2036. The industry revenue for 2027 is calculated at USD 4.44 billion.
Get more details on this report
Request Free Sample ReportHereditary Angioedema Therapeutics Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 70.56% market share in 2026, supported by established diagnosis pathways, specialist care access, and strong adoption of approved therapies for acute and preventive treatment.
- Asia Pacific is projected to grow at an 8.48% CAGR, driven by improving rare disease recognition, broader therapy access, stronger healthcare delivery, and increasing diagnosis leading to greater treatment uptake.
Segment Momentum
- C1-esterase Inhibitor held a 54.81% share in 2026 due to its established clinical use, physician familiarity, and direct relevance to the underlying deficiency, supporting dependable disease control and continuity of care.
- Bradykinin B2 Receptor Antagonists are the fastest-growing treatment segment because they target the bradykinin pathway responsible for acute symptoms, aligning with increasing demand for precise and rapid episode management.
Market Expansion Drivers
- Expanding availability of targeted biologics and kallikrein inhibitors improving treatment outcomes.
- Rising early diagnosis and awareness of rare genetic disorders increasing patient treatment uptake.
- Strong pharmaceutical R&D pipeline accelerating approval of novel oral and injectable therapies.
Leading Market Participants
- Prominent companies in the hereditary angioedema therapeutics market include Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Sanofi S.A. (France), BioCryst Pharmaceuticals, Inc. (United States), Ionis Pharmaceuticals, Inc. (United States), KalVista Pharmaceuticals, Inc. (United States), Pharming Group N.V. (Netherlands), Pharvaris N.V. (Netherlands), Arrowhead Pharmaceuticals, Inc. (United States), Adverum Biotechnologies, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 4.1 billion
- 2027 Estimated Market Size: USD 4.44 billion.
- Projected Market Size: USD 10.52 billion by 2036
- Growth Forecast: 9.88% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: C1-esterase Inhibitor (Treatment) | Prophylaxis (End-use) | Subcutaneous (Route of Administration)
- Emerging Opportunity Segment: Bradykinin B2 Receptor Antagonist (Treatment) | Prophylaxis (End-use) | Oral (Route of Administration)
Market Growth Drivers and Industry Trends
Expanding availability of targeted biologics and kallikrein inhibitors improving treatment outcomes
The hereditary angioedema therapeutics market growth is being supported by broader access to targeted biologics and kallikrein inhibitors that address key pathways involved in disease attacks. These therapies can provide more precise disease control than conventional symptomatic approaches, helping reduce the frequency or severity of episodes and improving patients’ ability to manage a chronic and unpredictable condition. As treatment options become more differentiated across preventive and on-demand use, physicians can select therapies according to attack patterns, treatment response, and individual patient needs, strengthening adoption of advanced therapies in clinical practice.
Rising early diagnosis and awareness of rare genetic disorders increasing patient treatment uptake
Greater recognition of hereditary angioedema symptoms among physicians and patients is helping shorten the path from unexplained recurrent swelling to appropriate diagnosis and treatment. The hereditary angioedema therapeutics market will benefit as awareness initiatives encourage evaluation of individuals with recurring episodes and relevant family histories, bringing previously undiagnosed patients into formal care pathways. Earlier identification also enables preventive treatment decisions and better attack management, while improved understanding of the inherited nature of the disorder can encourage family screening and identification of additional patients requiring long-term therapeutic support.
Strong pharmaceutical R&D pipeline accelerating approval of novel oral and injectable therapies
A strong development pipeline is broadening the therapeutic landscape by focusing on oral and injectable approaches that can improve convenience, dosing flexibility, and disease control. Continued innovation in the hereditary angioedema therapeutics market is encouraging research into therapies with differentiated mechanisms, potentially expanding options for patients who experience inadequate response, tolerability challenges, or administration limitations with existing treatments. Development activity across preventive and acute-care applications also supports a more diversified treatment ecosystem as regulatory programs advance promising candidates through clinical development.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding availability of targeted biologics and kallikrein inhibitors improving treatment outcomes | 2.00% | High | North America, Europe | High | Near Term |
| Rising early diagnosis and awareness of rare genetic disorders increasing patient treatment uptake | 1.60% | High | North America, Europe, Asia Pacific | High | Near Term |
| Strong pharmaceutical R&D pipeline accelerating approval of novel oral and injectable therapies | 1.50% | High | North America, Europe | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the hereditary angioedema therapeutics market, accounting for a 70.56% share in 2026, supported by strong awareness of hereditary angioedema, established diagnostic capabilities, and broad access to specialized treatment. The region benefits from a mature healthcare infrastructure with greater availability of targeted therapies and specialist-led care, while ongoing improvements in disease recognition and diagnosis help more patients receive appropriate management. Favorable treatment access, established reimbursement pathways, and continued investment in rare-disease care further reinforce North America's leading position in the market.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to represent the fastest-growing regional market, driven by improving recognition of hereditary angioedema and the gradual expansion of specialized healthcare services. Greater efforts to strengthen rare-disease diagnosis, increasing healthcare expenditure, and improving access to advanced therapeutics are supporting market development across the region. In addition, rising awareness among healthcare professionals and patients, combined with expanding healthcare infrastructure and greater attention to unmet needs in rare diseases, is creating opportunities for broader adoption of hereditary angioedema treatments.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Comprehensive Rare Disease CareGermany integrates specialized diagnostic services with modern hereditary angioedema therapeutics to support individualized patient management. Healthcare providers in Germany focus on preventive treatment approaches and coordinated care for patients requiring long-term disease control.
France 🇫🇷
Integrated Patient ManagementFrance advances hereditary angioedema therapeutics through coordinated care models that combine specialist expertise with improved diagnostic capabilities. Healthcare providers in France focus on optimizing prophylactic treatment use while supporting effective management of acute episodes.
Italy 🇮🇹
Specialized Immunology ServicesItaly strengthens the hereditary angioedema therapeutics market through specialized immunology centers and structured patient management programs. Healthcare providers in Italy continue incorporating targeted therapies and individualized treatment plans to improve disease control and patient quality of life.
Japan 🇯🇵
Personalized Treatment AccessJapan prioritizes improved access to innovative hereditary angioedema therapeutics supported by accurate diagnosis and specialized clinical care. Healthcare organizations in Japan continue strengthening treatment pathways that balance acute attack management with preventive therapy options.
South Korea 🇰🇷
Modern Prophylactic StrategiesSouth Korea is expanding the use of hereditary angioedema therapeutics through increased adoption of preventive treatment regimens and specialized patient care. Clinical providers in South Korea emphasize timely diagnosis and individualized therapy selection to improve long-term disease management.
United States 🇺🇸
Targeted Biologic AdoptionThe U.S. hereditary angioedema therapeutics market emphasizes advanced biologics, prophylactic therapies, and personalized treatment strategies for long-term disease management. Healthcare providers in the U.S. continue improving patient access to innovative therapies that reduce attack frequency and support self-administration.
Segment Leadership and Growth Trends
Hereditary Angioedema Therapeutics Market Share (%), by Treatment, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTreatment Segment Analysis: C1-esterase Inhibitor (Largest Segment) vs Bradykinin B2 Receptor Antagonist (Fastest-Growing Segment)
C1-esterase inhibitor therapies held the largest share of the hereditary angioedema therapeutics market in 2026, accounting for a 54.81% share. Their established position reflects the importance of replacing or supplementing deficient regulatory activity associated with hereditary angioedema and controlling the underlying pathway responsible for swelling episodes. The availability of established therapeutic approaches for managing acute attacks and preventing recurrent episodes supports continued demand for C1-esterase inhibitors. Their role across different aspects of hereditary angioedema management reinforces their strong position within the treatment landscape.
Bradykinin B2 receptor antagonist represents the fastest-growing treatment segment, supported by increasing attention to therapies that directly target bradykinin-mediated mechanisms involved in hereditary angioedema attacks. Targeted inhibition of this pathway provides a focused therapeutic approach for managing symptoms and addressing the biological processes underlying acute swelling episodes. Continued emphasis on rapid and mechanism-specific treatment, together with the need for effective management of attacks, is encouraging greater adoption of bradykinin B2 receptor antagonists and expanding their role within the market.
End-use Segment Analysis: Prophylaxis (Largest & Fastest-Growing Segment)
Prophylaxis dominated the hereditary angioedema therapeutics market in 2026, representing the largest share and also emerging as the fastest-growing end-use segment. Its importance is driven by the recurrent and potentially severe nature of hereditary angioedema attacks, creating a strong need for preventive treatment strategies that reduce episode frequency and improve disease control. Prophylactic therapy can support greater predictability in disease management while reducing the burden associated with repeated acute attacks. Increasing emphasis on long-term prevention, improved quality of life, and proactive management of chronic hereditary angioedema is reinforcing demand for prophylactic therapeutic approaches.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Treatment | C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others | C1-esterase Inhibitor | Bradykinin B2 Receptor Antagonist |
| End-use | Prophylaxis, On-demand | Prophylaxis | Prophylaxis |
| Route of Administration | Intravenous, Subcutaneous, Oral | Subcutaneous | Oral |
Competitive Landscape and Market Positioning
Prominent players in the hereditary angioedema therapeutics market:
1. Takeda Pharmaceutical Company Limited (Japan)
2. CSL Limited (Australia)
3. Sanofi S.A. (France)
4. BioCryst Pharmaceuticals Inc. (United States)
5. Ionis Pharmaceuticals Inc. (United States)
6. KalVista Pharmaceuticals Inc. (United States)
7. Pharming Group N.V. (Netherlands)
8. Pharvaris N.V. (Netherlands)
9. Arrowhead Pharmaceuticals Inc. (United States)
10. Adverum Biotechnologies Inc. (United States)
The hereditary angioedema therapeutics market is seeing increased competition centered on the development of faster-acting and patient-friendly treatment options. Innovation in self-administration therapies and long-duration preventive solutions is improving treatment convenience, while differentiated product profiles are becoming essential for strengthening market presence.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited (Japan) | |||||||
| CSL Limited (Australia) | |||||||
| Sanofi S.A. (France) | |||||||
| BioCryst Pharmaceuticals Inc. (United States) | |||||||
| Ionis Pharmaceuticals Inc. (United States) | |||||||
| KalVista Pharmaceuticals Inc. (United States) | |||||||
| Pharming Group N.V. (Netherlands) | |||||||
| Pharvaris N.V. (Netherlands) | |||||||
| Arrowhead Pharmaceuticals Inc. (United States) | |||||||
| Adverum Biotechnologies Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Ionis Pharmaceuticals | Aug-25 | The FDA approved DAWNZERA (donidalorsen), the first RNA-targeted prophylactic therapy for hereditary angioedema in patients aged 12 and older. Clinical data from the Phase 3 OASIS HAE trial demonstrated significant reductions in monthly attack rates, establishing a new therapeutic class for long-term HAE management. |
| BioCryst Pharmaceuticals | Jun-25 | BioCryst presented Phase 3 data for ORLADEYO (berotralstat) in pediatric patients aged 2 to 11. The APeX-P study showed an 86% decline in treated attacks over 12 weeks, supporting the drug’s efficacy in younger populations and facilitating the filing of a pediatric NDA for oral granule formulations. |
| CSL Behring | Apr-25 | CSL Behring launched ANDEMBRY (garadacimab) in Japan for the prevention of acute HAE attacks in patients aged 12 and older. Following regulatory approval and National Health Insurance listing, the rollout targets a significant patient population in the Japanese market, strengthening CSL Behring’s portfolio of monoclonal antibody-based prophylaxis. |
| KalVista Pharmaceuticals | Apr-25 | KalVista entered a licensing agreement with Kaken Pharmaceutical to commercialize sebetralstat in Japan. This strategic partnership grants Kaken commercial rights for the investigational oral on-demand treatment, expanding the product’s projected market access in the region upon potential future approval. |
| Ionis Pharmaceuticals | Dec-23 | Ionis Pharmaceuticals licensed exclusive European commercialization rights for donidalorsen to Otsuka Pharmaceutical. This agreement aligns the resources of two major players to support the clinical advancement and future market entry of the RNA-targeted prophylactic HAE candidate across European territories. |
| Pharming Group; Orchard Therapeutics | Jul-21 | Pharming Group and Orchard Therapeutics established a strategic collaboration to develop OTL-105, an ex vivo autologous hematopoietic stem cell gene therapy for HAE. This partnership aims to leverage gene-editing technology to explore curative-intent options, marking an entry into next-generation therapeutic modalities for HAE patients. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Hereditary Angioedema Therapeutics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Patient Age Group | Pediatric, Adolescent, Adult |
| Disease Severity | Mild, Moderate, Severe |
| Payment Type | Private/Commercial Insurance, Government/Public Insurance, Self-Pay/Uninsured |
Hereditary Angioedema Therapeutics Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Patient Identification and Diagnostic Pathway Optimization |
|
| Treatment Pathway Evolution and Switching Dynamics |
|
| Market Access and Orphan Drug Reimbursement Landscape |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the hereditary angioedema therapeutics market?
What is the forecasted size of the hereditary angioedema therapeutics industry?
How are targeted biologics and kallikrein inhibitors reshaping treatment strategies in the hereditary angioedema therapeutics market?
How is rising early diagnosis and awareness affecting patient uptake in this market?
Why is C1-esterase Inhibitor the leading treatment in the hereditary angioedema therapeutics market?
What is driving the growth of Bradykinin B2 Receptor Antagonists in the hereditary angioedema therapeutics market?
Why does North America lead the hereditary angioedema therapeutics market?
Why is Asia Pacific the fastest-growing region in the hereditary angioedema therapeutics market?
Which companies are driving growth in the hereditary angioedema therapeutics landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization